Cannabis Report
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, Phaeton, $Pistol Pete$
Search This Board: 
Last Post: 6/19/2018 7:34:40 PM - Followers: 399 - Board type: Free - Posts Today: 16


Many Afrezza users have reported rapid drops in A1c

Yeah, but in the only clinical trials that compared Afrezza to rapid acting insulins, Afrezza did no such thing.

Straight from the label:

Absolute HgA1c reduction:
Afrezza : 0.21
Rapid I : 0.40

% of patients reducing by 7% or more:
Affreza: 13.8%
Rapid I: 27.1%

And there is your problem. Tweets do not counter clinical trial data.

Afrezza avoids the needle, for sure.But is it better?

It has a faster/narrower spike. BUT, to take advantage of this, the user need to know how to use it.

Perhaps a few users have got it down, and do better. But that does not work for the masses.

MNKD really needs to figure out how to work with the new electronic glucose monitors to solve this issue.        

 p.s. Reading the Mannkind report at FDA.GOV provides plenty of clues why Afrezza is a failure.        

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Alfred E. Mann, Founder (Deceased)

Alfred E. Mann had been one of MNKD's directors since April 1999, Chairman of the Board since December 2001 and  Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio 

Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MNKD News: Statement of Changes in Beneficial Ownership (4) 06/14/2018 05:02:20 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 06/14/2018 05:01:03 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 06/14/2018 05:00:37 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 06/14/2018 05:00:11 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 06/14/2018 04:59:19 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#28669  Sticky Note $MNKD MannKind Successfully Completes Phase 1 Trial of $Pistol Pete$ 06/07/18 11:06:18 AM
#27521  Sticky Note From the MNKD proboards -->> TTIME 02/14/18 02:49:38 PM
#23541  Sticky Note Buffalo teacher a key advocate in breakthrough diabetes drug Phaeton 05/19/17 12:07:29 PM
#28898   Better buckle in imo TTIME 06/19/18 07:34:40 PM
#28897   DUDE! We're make some mad money now! SidVicious 06/19/18 05:58:25 PM
#28896   And I beg your pardon, but it's your parkourstar 06/19/18 04:46:42 PM
#28895   That is not good logic. I pointed this parkourstar 06/19/18 04:33:27 PM
#28894   $MNKD Daily and Weekly Chart http://stockchar $Pistol Pete$ 06/19/18 04:31:15 PM
#28893   Wow, you're a wealth of knowledge...ahhh NOT! TTIME 06/19/18 04:17:23 PM
#28892   Wrong..was that you and parky buying ? TTIME 06/19/18 04:15:35 PM
#28891   $MNKD beautiful close ;-) Go $MNKD $Pistol Pete$ 06/19/18 04:10:16 PM
#28890   $MNKD look what it is now. Leg building $Pistol Pete$ 06/19/18 03:18:03 PM
#28889   The reason why refills are low is due SidVicious 06/19/18 11:16:58 AM
#28888   I hate to be the one to tell parkourstar 06/19/18 11:07:21 AM
#28886   TIMBER!!!! Not so nice open. Looks like it's SidVicious 06/19/18 09:37:09 AM
#28885   It's not difficult. It actually is very SidVicious 06/19/18 09:30:06 AM
#28884   Actually, re-reading the article, it makes using afizzle parkourstar 06/19/18 09:17:10 AM
#28883   Tells you all you need to know: parkourstar 06/19/18 09:14:03 AM
#28882   $MNKD It is a good level entry and $Pistol Pete$ 06/18/18 06:40:41 PM
#28881   Good to see and clearly would have been Hypi 06/18/18 06:25:45 PM
#28880   Nice close ;-) $Pistol Pete$ 06/18/18 04:25:08 PM
#28879   Hope for couple more filings on the buy $Pistol Pete$ 06/18/18 03:10:54 PM
#28878   $MNKD insiders won’t buy back shares if they $Pistol Pete$ 06/18/18 03:09:14 PM
#28877   It will be big time moving IMO $Pistol Pete$ 06/18/18 01:48:22 PM
#28876   It will be interesting to see what happens SidVicious 06/18/18 01:33:49 PM
#28875   Yes it is $Pistol Pete$ 06/18/18 01:32:03 PM
#28874   Every time when it hit my $ bounce back $Pistol Pete$ 06/18/18 01:31:54 PM
#28873   Yep, organic like Arsenic. SidVicious 06/18/18 01:19:57 PM
#28872   Good Stuff !!! TTIME 06/18/18 12:21:55 PM
#28871   $MNKD Recommendations for Initiating Use of Afrezza Inhaled $Pistol Pete$ 06/18/18 12:06:25 PM
#28870   Back to $1.91....very organic $Pistol Pete$ 06/18/18 11:05:05 AM
#28869   Under 1.90 and possibly on to 1.80 with SidVicious 06/18/18 09:40:26 AM
#28868   D E SHAW likes MNKD amongst others )) TTIME 06/16/18 11:39:54 PM
#28867   $MNKD MannKind - Insider Buys As Weekly Afrezza $Pistol Pete$ 06/16/18 12:57:34 AM
#28866   Thank you for making my point....The ATM is Aloha96707 06/16/18 12:42:20 AM
#28865   495,550 to be exact $Pistol Pete$ 06/15/18 09:36:08 PM
#28864   Big block buying going on - 400K share STOCKSEEK 06/15/18 08:02:17 PM
#28863   Yeah, well, over the next few months, Mannkind parkourstar 06/15/18 07:59:10 PM
#28862   "For the quarter ended March 31, 2018, we parkourstar 06/15/18 07:43:38 PM
#28861   Thats your opinion,NOT mine TTIME 06/15/18 06:49:53 PM
#28860   It's obvious you don't listen to MNKD's CC. Aloha96707 06/15/18 06:02:47 PM
#28859   EveryTTIME you say it's a new day, the SidVicious 06/15/18 04:40:24 PM
#28858   Not active when the stock is below $2.50? parkourstar 06/15/18 03:27:22 PM
#28857   It's a NEW DAY ! TTIME 06/15/18 02:38:51 PM
#28856   This is all good and thanks for sharing $Pistol Pete$ 06/15/18 01:53:16 PM
#28855   See how Mike confirms in a diplomatic way SidVicious 06/15/18 10:34:46 AM
#28854 TTIME 06/15/18 09:54:49 AM
#28853   Tick tick shorts... STOCKSEEK 06/15/18 09:08:25 AM
#28852   That's not the way an ATM works... XenaLives 06/15/18 09:03:19 AM
#28851   Do we need to remind people that the Kouka06 06/15/18 08:15:12 AM
#28850   WRONG - The ATM is NOT ACTIVE when Kouka06 06/15/18 08:11:22 AM
#28849   LOL..Dude spin it any way you want to, TTIME 06/15/18 06:47:19 AM
#28848   "NEW SCRIPT NUMBERS: parkourstar 06/15/18 06:37:32 AM